Literature DB >> 10884941

Basal cell carcinoma--new aspects of diagnosis and treatment.

A M Wennberg1.   

Abstract

The incidence of basal cell carcinoma is increasing. New aspects of diagnosis and treatment are discussed in this thesis. Interferon can be used for the treatment of BCC. In paper I, 15 patients received 13.5 x 10(6) IU of alfa-2b-interferon intralesionally. Four patients healed completely whereas a 75% reduction was seen in 5 cases. Intralesional alfa-2b-interferon can reduce the number of excisions during Mohs Micrographic Surgery. Topical photodynamic therapy involves the application of ALA on the skin. In tumour cells selectively, formation of the photosensitizer Pp IX occurs. After 4 hours of occlusion of ALA the area is irradiated with light at a wavelength of 630 nm. Tumour cells are selectively destroyed during this procedure. 144/157 SBCC healed in this series and 14/18 Mb Bowen (paper II). The method is only suited for thin BCCs as the result on thicker lesions is poor (2/10 healed). The cosmetic result was generally good or excellent. Another way of utilising the tumour selectivity of Pp IX is for diagnostic purposes. Instead of illuminating with 630 nm, 365, 366 and 405 nm are used to induce a specific fluorescence. In the present paper (III), 50% of facial BCCs with ill-defined borders could be completely visualised and another 23% partly outlined. The technique did not seem to work in 27% of the cases. The critical factor using ALA is probably the relatively poor penetrance through the skin. In paper IV, microdialysis is used for pharmacokinetic studies of ALA for the first time. The concentration of ALA increases rapidly in lesional skin whereas there is virtually no penetration in healthy skin. Also, the blood perfusion in BCCs was investigated by means of laser Doppler Perfusion Imager. The perfusion in skin overlying a BCC was 2.5 fold higher compared to normal skin. For BCCs with ill-defined borders Mohs Micrographic Surgery is generally recommended. Regarding Mohs Micrographic Surgery, Sweden is underserved as only 1% of BCCs are treated with Mohs Micrographic Surgery as opposed to 30% in the US. Consequently, the Swedish cases are probably more severe. The long-term results are reported in paper V. Two hundred and twenty-eight tumours were followed for at least 5 years. The rate of recurrence was 8%. This figure is slightly higher than in international materials but surprisingly low considering the type of tumours.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10884941

Source DB:  PubMed          Journal:  Acta Derm Venereol Suppl (Stockh)        ISSN: 0365-8341


  6 in total

1.  Successful treatment of squamous cell carcinoma of the lower eyelid with intralesional cidofovir.

Authors:  D Calista; L Riccioni; L Coccia
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

2.  Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions.

Authors:  M R Hussein; D A H Elsers; S A Fadel; A-E M Omar
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

3.  Tazarotene induces apoptosis in human basal cell carcinoma via activation of caspase-8/t-Bid and the reactive oxygen species-dependent mitochondrial pathway.

Authors:  Chieh-Shan Wu; Gwo-Shing Chen; Ping-Yi Lin; I-Hong Pan; San-Tang Wang; Sheng Hao Lin; Hsin-Su Yu; Chi-Chen Lin
Journal:  DNA Cell Biol       Date:  2014-06-13       Impact factor: 3.311

4.  [Cutaneous epithelial tumors. Molecular biology and pathogenesis-based therapy].

Authors:  J Reifenberger; M P Schön
Journal:  Hautarzt       Date:  2003-12       Impact factor: 0.751

5.  Langerhans cells in cutaneous tumours: immunohistochemistry study using a computer image analysis system.

Authors:  Mario Ribeiro De Melo; Jorge Luiz Araújo Filho; Vasco José Ramos Patu; Marcos Cezar Feitosa Machado; Luciano Albuquerque Mello; Luiz B Carvalho
Journal:  J Mol Histol       Date:  2006-11-02       Impact factor: 3.156

6.  A Clinical Study of Basal Cell Carcinoma.

Authors:  Emina Kasumagic-Halilovic; Mediha Hasic; Nermina Ovcina-Kurtovic
Journal:  Med Arch       Date:  2019-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.